AR074826A1 - Regimen de dosificacion para un agonista de los receptores de s1p - Google Patents
Regimen de dosificacion para un agonista de los receptores de s1pInfo
- Publication number
- AR074826A1 AR074826A1 ARP090105010A ARP090105010A AR074826A1 AR 074826 A1 AR074826 A1 AR 074826A1 AR P090105010 A ARP090105010 A AR P090105010A AR P090105010 A ARP090105010 A AR P090105010A AR 074826 A1 AR074826 A1 AR 074826A1
- Authority
- AR
- Argentina
- Prior art keywords
- agonist
- receptors
- medicament
- pharmaceutically acceptable
- compound
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 4
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 3
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 abstract 1
- 229960000556 fingolimod Drugs 0.000 abstract 1
- LRFKWQGGENFBFO-UHFFFAOYSA-N fingolimod phosphate Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)COP(O)(O)=O)C=C1 LRFKWQGGENFBFO-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 229940075993 receptor modulator Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los moduladores o agonistas de los receptores de S1P se administran siguiendo un régimen de dosificación en donde, durante los días iniciales del tratamiento, la dosificación diaria es más baja que la dosificación diaria convencional. Reivindicación 1: El uso de un modulador o agonista de los receptores de S1P en la fabricación de un medicamento para utilizarse en el tratamiento de una enfermedad crónica larga en un paciente, en donde este medicamento se administra de tal manera a un sujeto, que la disminución diaria en la frecuencia cardíaca es de aproximadamente 2 latidos/minuto o menos. Reivindicación 10: El uso o método de acuerdo con cualquiera de las reivindicaciones anteriores, en donde el modulador o agonista de los receptores de S1P se selecciona a partir del compuesto A (FTY720), una sal farmacéuticamente aceptable del mismo, y el compuesto B (fosfato de FTY720), o las sales farmacéuticamente aceptables del mismo. Reivindicación 14: El uso, método, o kit de acuerdo con cualquiera de las reivindicaciones anteriores, en donde la enfermedad es esclerosis múltiple.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13967208P | 2008-12-22 | 2008-12-22 | |
| US21853009P | 2009-06-19 | 2009-06-19 | |
| US24671509P | 2009-09-29 | 2009-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074826A1 true AR074826A1 (es) | 2011-02-16 |
Family
ID=41667217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090105010A AR074826A1 (es) | 2008-12-22 | 2009-12-21 | Regimen de dosificacion para un agonista de los receptores de s1p |
Country Status (40)
| Country | Link |
|---|---|
| US (11) | US20110257133A1 (es) |
| EP (7) | EP4098256A1 (es) |
| JP (6) | JP2012513401A (es) |
| KR (1) | KR101347919B1 (es) |
| CN (1) | CN102264359A (es) |
| AR (1) | AR074826A1 (es) |
| AU (1) | AU2009330176C9 (es) |
| BR (1) | BRPI0923500A2 (es) |
| CA (1) | CA2747802C (es) |
| CL (2) | CL2011001529A1 (es) |
| CO (1) | CO6390117A2 (es) |
| CR (1) | CR20110274A (es) |
| CU (1) | CU20110136A7 (es) |
| CY (4) | CY1116990T1 (es) |
| DK (3) | DK3453387T3 (es) |
| EA (1) | EA201100978A1 (es) |
| EC (1) | ECSP11011222A (es) |
| ES (3) | ES2810823T3 (es) |
| FR (1) | FR20C1060I1 (es) |
| HN (1) | HN2011001759A (es) |
| HR (3) | HRP20151190T1 (es) |
| HU (4) | HUE048717T4 (es) |
| IL (3) | IL213170A0 (es) |
| LT (3) | LT3409274T (es) |
| MA (1) | MA32981B1 (es) |
| ME (2) | ME03594B (es) |
| MX (2) | MX2011006623A (es) |
| NO (1) | NO2020038I1 (es) |
| NZ (1) | NZ593065A (es) |
| PE (1) | PE20120337A1 (es) |
| PL (3) | PL2379067T3 (es) |
| PT (3) | PT3409274T (es) |
| RS (2) | RS59857B1 (es) |
| SG (1) | SG171404A1 (es) |
| SI (3) | SI2379067T1 (es) |
| TN (1) | TN2011000272A1 (es) |
| TW (1) | TW201028143A (es) |
| UY (1) | UY32352A (es) |
| WO (1) | WO2010075239A1 (es) |
| ZA (2) | ZA201103863B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR070842A1 (es) * | 2008-03-17 | 2010-05-05 | Actelion Pharmaceuticals Ltd | Regimen de dosificacion para un agonista de receptor selectivo de s1p1 |
| EP4098256A1 (en) | 2008-12-22 | 2022-12-07 | Novartis AG | Dosage regimen for a s1p receptor agonist |
| WO2011041146A2 (en) | 2009-09-29 | 2011-04-07 | Novartis Ag | Dosage regimen of an s1p receptor modulator |
| US20110124605A1 (en) * | 2009-11-20 | 2011-05-26 | Shreeram Aradhye | Use of an S1P Receptor Agonist |
| CN103221391B (zh) | 2010-01-27 | 2018-07-06 | 艾尼纳制药公司 | (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法 |
| MX2012012925A (es) * | 2010-05-06 | 2012-12-17 | Novartis Ag | Regimen de dosificacion de derivados de sulfuro de diarilo. |
| EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
| FR2968556B1 (fr) | 2010-12-13 | 2013-12-27 | Centre Nat Rech Scient | Inhibiteurs des infections a vih et leurs utilisations |
| EP2675893B1 (en) * | 2011-02-18 | 2019-01-09 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
| AR085749A1 (es) | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
| WO2012162392A1 (en) * | 2011-05-23 | 2012-11-29 | Timothy Hla | Endothelium protective materials and methods of use |
| TW201320994A (zh) | 2011-10-11 | 2013-06-01 | Novartis Ag | 投藥療程 |
| EP2885266B1 (en) | 2012-08-17 | 2020-03-18 | Actelion Pharmaceuticals Ltd | Process for the preparation of (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process |
| JP6542678B2 (ja) * | 2013-03-06 | 2019-07-10 | アコーダ セラピューティクス インコーポレイテッド | 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法 |
| WO2015053878A1 (en) | 2013-10-11 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same |
| US10675254B2 (en) | 2013-10-11 | 2020-06-09 | Teikoku Seiyaku Co., Ltd. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
| CA2943598C (en) * | 2014-04-10 | 2023-03-07 | Novartis Ag | S1p modulator immediate release dosage regimen |
| UA122064C2 (uk) | 2014-12-11 | 2020-09-10 | Актеліон Фармасьютікалз Лтд | Схема дозування для селективного агоніста рецептора s1p1 |
| CN107405332A (zh) * | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
| CA2973540A1 (en) | 2015-02-26 | 2016-09-01 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
| EP3582772A1 (en) | 2017-02-16 | 2019-12-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| MA47503A (fr) | 2017-02-16 | 2021-04-21 | Arena Pharm Inc | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales |
| EP4051250A1 (en) | 2019-10-31 | 2022-09-07 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| WO2021158838A1 (en) | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor modulator |
| WO2021158848A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor agonist |
| CN113332435B (zh) * | 2021-06-18 | 2022-10-18 | 广州中医药大学(广州中医药研究院) | 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0627406T3 (da) | 1992-10-21 | 1999-07-12 | Taito Co | 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler |
| WO2002018395A1 (en) | 2000-08-31 | 2002-03-07 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
| CN1652757B (zh) | 2002-05-16 | 2012-02-08 | 诺瓦提斯公司 | Edg受体结合剂在癌症中的应用 |
| WO2005025553A2 (en) * | 2003-09-12 | 2005-03-24 | Neuronova Ab | Treatment of disorders of nervous systemsystem with fty720 |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| SG158096A1 (en) * | 2004-11-29 | 2010-01-29 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
| EP1688141A1 (en) * | 2005-01-31 | 2006-08-09 | elbion AG | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
| EP1850689A4 (en) * | 2005-02-10 | 2013-05-22 | G I View Ltd | TECHNIQUES FOR DISPLACING A GASTROINTESTINAL TOOL EQUIPPED WITH A GUIDING ELEMENT |
| EP3120833A1 (en) * | 2007-10-12 | 2017-01-25 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| AR070842A1 (es) * | 2008-03-17 | 2010-05-05 | Actelion Pharmaceuticals Ltd | Regimen de dosificacion para un agonista de receptor selectivo de s1p1 |
| WO2009155475A1 (en) * | 2008-06-20 | 2009-12-23 | Novartis Ag | Paediatric compositions for treating1 multiple sclerosis |
| KR101660555B1 (ko) * | 2008-12-22 | 2016-09-27 | 노파르티스 아게 | Ｓ１ｐ 수용체 효능제의 투여 요법 |
| EP4098256A1 (en) | 2008-12-22 | 2022-12-07 | Novartis AG | Dosage regimen for a s1p receptor agonist |
-
2009
- 2009-12-21 EP EP22187007.4A patent/EP4098256A1/en active Pending
- 2009-12-21 EP EP18179301.9A patent/EP3409274B1/en active Active
- 2009-12-21 LT LTEP18179301.9T patent/LT3409274T/lt unknown
- 2009-12-21 SI SI200931311T patent/SI2379067T1/sl unknown
- 2009-12-21 PT PT181793019T patent/PT3409274T/pt unknown
- 2009-12-21 DK DK18201062.9T patent/DK3453387T3/da active
- 2009-12-21 LT LTEP18201062.9T patent/LT3453387T/lt unknown
- 2009-12-21 SI SI200932015T patent/SI3409274T1/sl unknown
- 2009-12-21 ME MEP-2019-339A patent/ME03594B/me unknown
- 2009-12-21 SG SG2011037629A patent/SG171404A1/en unknown
- 2009-12-21 RS RS20191546A patent/RS59857B1/sr unknown
- 2009-12-21 NZ NZ593065A patent/NZ593065A/xx not_active IP Right Cessation
- 2009-12-21 SI SI200932080T patent/SI3453387T1/sl unknown
- 2009-12-21 MX MX2011006623A patent/MX2011006623A/es unknown
- 2009-12-21 KR KR1020117017073A patent/KR101347919B1/ko active IP Right Grant
- 2009-12-21 EP EP09797234.3A patent/EP2379067B1/en not_active Revoked
- 2009-12-21 AU AU2009330176A patent/AU2009330176C9/en not_active Withdrawn - After Issue
- 2009-12-21 HU HUE18179301A patent/HUE048717T4/hu unknown
- 2009-12-21 PL PL09797234T patent/PL2379067T3/pl unknown
- 2009-12-21 ME MEP-2020-156A patent/ME03802B/me unknown
- 2009-12-21 BR BRPI0923500-0A patent/BRPI0923500A2/pt not_active Application Discontinuation
- 2009-12-21 MA MA34034A patent/MA32981B1/fr unknown
- 2009-12-21 DK DK18179301.9T patent/DK3409274T3/da active
- 2009-12-21 ES ES18201062T patent/ES2810823T3/es active Active
- 2009-12-21 HU HUE09797234A patent/HUE026869T2/en unknown
- 2009-12-21 EP EP15158251.7A patent/EP2907511A1/en not_active Withdrawn
- 2009-12-21 CA CA2747802A patent/CA2747802C/en active Active
- 2009-12-21 WO PCT/US2009/068888 patent/WO2010075239A1/en active Application Filing
- 2009-12-21 EP EP16182876.9A patent/EP3120844A1/en not_active Withdrawn
- 2009-12-21 PT PT97972343T patent/PT2379067E/pt unknown
- 2009-12-21 ES ES09797234.3T patent/ES2552823T3/es active Active
- 2009-12-21 EA EA201100978A patent/EA201100978A1/ru unknown
- 2009-12-21 UY UY0001032352A patent/UY32352A/es not_active Application Discontinuation
- 2009-12-21 PT PT182010629T patent/PT3453387T/pt unknown
- 2009-12-21 US US13/141,552 patent/US20110257133A1/en not_active Abandoned
- 2009-12-21 HU HUE18201062A patent/HUE052048T2/hu unknown
- 2009-12-21 PL PL18201062T patent/PL3453387T3/pl unknown
- 2009-12-21 DK DK09797234.3T patent/DK2379067T3/en active
- 2009-12-21 EP EP18201062.9A patent/EP3453387B1/en active Active
- 2009-12-21 PE PE2011001265A patent/PE20120337A1/es not_active Application Discontinuation
- 2009-12-21 ES ES18179301T patent/ES2760607T3/es active Active
- 2009-12-21 RS RS20200900A patent/RS60666B1/sr unknown
- 2009-12-21 TW TW098143960A patent/TW201028143A/zh unknown
- 2009-12-21 CN CN2009801518640A patent/CN102264359A/zh active Pending
- 2009-12-21 EP EP20160225.7A patent/EP3677260A1/en active Pending
- 2009-12-21 AR ARP090105010A patent/AR074826A1/es not_active Application Discontinuation
- 2009-12-21 JP JP2011542521A patent/JP2012513401A/ja not_active Withdrawn
- 2009-12-21 US US12/642,892 patent/US20100160259A1/en not_active Abandoned
- 2009-12-21 PL PL18179301T patent/PL3409274T3/pl unknown
-
2011
- 2011-05-25 ZA ZA2011/03863A patent/ZA201103863B/en unknown
- 2011-05-25 CR CR20110274A patent/CR20110274A/es not_active Application Discontinuation
- 2011-05-26 IL IL213170A patent/IL213170A0/en unknown
- 2011-05-26 TN TN2011000272A patent/TN2011000272A1/fr unknown
- 2011-06-17 MX MX2021010759A patent/MX2021010759A/es unknown
- 2011-06-21 CL CL2011001529A patent/CL2011001529A1/es unknown
- 2011-06-22 EC EC2011011222A patent/ECSP11011222A/es unknown
- 2011-06-22 HN HN2011001759A patent/HN2011001759A/es unknown
- 2011-06-22 CU CU20110136A patent/CU20110136A7/es unknown
- 2011-06-23 CO CO11079290A patent/CO6390117A2/es not_active Application Discontinuation
-
2012
- 2012-08-06 ZA ZA2012/05942A patent/ZA201205942B/en unknown
-
2013
- 2013-05-31 CL CL2013001558A patent/CL2013001558A1/es unknown
- 2013-09-06 US US14/020,058 patent/US20140066657A1/en not_active Abandoned
-
2014
- 2014-01-31 US US14/169,660 patent/US20140148415A1/en not_active Abandoned
- 2014-04-10 JP JP2014080892A patent/JP2014144970A/ja not_active Withdrawn
-
2015
- 2015-10-14 JP JP2015202669A patent/JP2016135752A/ja not_active Withdrawn
- 2015-11-06 HR HRP20151190TT patent/HRP20151190T1/hr unknown
- 2015-11-30 CY CY20151101084T patent/CY1116990T1/el unknown
- 2015-12-02 US US14/956,855 patent/US20160081949A1/en not_active Abandoned
-
2016
- 2016-05-23 US US15/161,778 patent/US20160263061A1/en not_active Abandoned
-
2017
- 2017-03-06 JP JP2017041331A patent/JP2017141238A/ja not_active Withdrawn
- 2017-03-21 US US15/465,091 patent/US20170189353A1/en not_active Abandoned
-
2018
- 2018-06-11 US US16/005,137 patent/US20180289638A1/en not_active Abandoned
- 2018-11-26 US US16/199,905 patent/US20190091180A1/en not_active Abandoned
-
2019
- 2019-05-22 JP JP2019095899A patent/JP7329965B2/ja active Active
- 2019-12-02 HR HRP20192175TT patent/HRP20192175T1/hr unknown
- 2019-12-03 CY CY20191101264T patent/CY1122812T1/el unknown
-
2020
- 2020-05-05 US US16/867,293 patent/US20200330407A1/en not_active Abandoned
- 2020-05-18 IL IL274756A patent/IL274756A/en unknown
- 2020-07-27 HR HRP20201167TT patent/HRP20201167T1/hr unknown
- 2020-08-03 CY CY20201100712T patent/CY1123255T1/el unknown
- 2020-11-17 LT LTPA2020005C patent/LTPA2020005I1/lt unknown
- 2020-11-18 NO NO2020038C patent/NO2020038I1/no unknown
- 2020-11-19 CY CY2020036C patent/CY2020036I2/el unknown
- 2020-11-19 FR FR20C1060C patent/FR20C1060I1/fr active Active
- 2020-11-19 HU HUS2000046C patent/HUS2000046I1/hu unknown
- 2020-11-23 IL IL278914A patent/IL278914A/en unknown
-
2021
- 2021-09-20 US US17/479,649 patent/US20220142949A1/en active Pending
-
2022
- 2022-04-21 JP JP2022070231A patent/JP2022103194A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074826A1 (es) | Regimen de dosificacion para un agonista de los receptores de s1p | |
| AR070842A1 (es) | Regimen de dosificacion para un agonista de receptor selectivo de s1p1 | |
| PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| ES2887042T1 (es) | Moduladores del receptor S1P para el tratamiento de la esclerosis múltiple | |
| ECSP045501A (es) | Moduladores de receptores nucleares de hormonas esteroideas triciclicos | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| RU2008139315A (ru) | Избирательные андрогенные рецепторные модуляторы | |
| CL2013002810A1 (es) | Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple. | |
| AR078588A1 (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
| CL2021001810A1 (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| MY195178A (en) | Composition for Treating Joint Disease and Kit Containing Same | |
| UY33453A (es) | Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina | |
| JP2018537514A5 (es) | ||
| BR112014009141A8 (pt) | regime de dosagem para um modulador ou agonista do receptor s1p | |
| AR088453A1 (es) | Regimen de dosificacion del agonista o modulador del receptor de s1p | |
| RU2014145351A (ru) | КОМБИНАЦИЯ АНАЛОГОВ СОМАТОСТАТИНА С ИНГИБИТОРАМИ 11β-ГИДРОКСИЛАЗЫ | |
| KR20110059634A (ko) | 6-디메틸아미노메틸-1-(3-메톡시-페닐)-사이클로헥산-1,3디올 및 파라세타몰을 포함하는 약제학적 병용물 | |
| ES2562416T3 (es) | Régimen de dosificación de derivados de sulfuro de diarilo | |
| TR201004720T1 (tr) | Majör depresif bozukluğun tedavisi için o-desmetil venlafaksin | |
| PH12016501026A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | |
| NO20024683D0 (no) | Terapier med oppdelte doser som har vaskul¶rt skadende aktivitet | |
| AR054126A1 (es) | Utilizacion de un benzoilderivado del 3-aminocarbazol para la produccion de un farmaco para el tratamiento de un desorden asociado a la produccion de prostaglandina e2 (pge2) | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |